PharmaFluidics Raises 2.7 Million Euros for Funding
PharmaFluidics has announced an additional 2.7 million Euros worth of funding to support its commercial launch and expand its analytical applications portfolio to biomarkers, diagnostics, and drug development.
Photo Credit: Vintage Tone/Shutterstock.com
PharmaFluidics has announced an additional 2.7 million Euros worth of funding to support its commercial launch and expand its analytical applications portfolio to biomarkers, diagnostics, and drug development.
Founded as a spin-off from the University of Brussels (VUB) in 2010 with a decade of top-level academic research as its foundation, PharmaFluidics aims to increase efficiency and resolution in liquid chromatography (LC) with ease of use and robustness, opening the way to further miniaturization and integration.
The company confirmed much of the funds will be used to speed up the commercialization of its range of microchipâbased chromatography cartridges. The cartridges are designed for use in biomarker, diagnostics, and
drug research and development applications across biotechnology and pharmaceutical industries. The remaining funds will be used to develop new application fields and reference cases, to broaden the market beyond the current pioneer users.
“These micro-chip columns have an immediate design and performance appeal to pioneer users in the pharmaceutical research and development segment,” said Johan Devenyns, Managing Director of PharmaFluidics. “We believe that ‘secondary features’ such as convenience of use, workflow simplification, column longevity and robustness, and reduced solvent consumption will allow for the future generations of microchip columns and cartridges to gain substantial market share. There is also a bright future for microchip-based columns to be used in combination with simplified, lower cost MS systems, which will become affordable in many more settings and places,” he added
PharmaFluidics also announced a presentation by Johan Devenyns at the “Knowledge for Growth” conference on 18 May 2017 in Ghent, Belgium.
The presentation will discuss micro-chip, pillar array columns, and monolithic chromatography separation beds and present examples of cell tryptic digests and plant tissue extracts to demonstrate the potential of the micro-chip technology. - L.B.
For more information on PharmaFluidics please visit: www.pharmafluidics.com
For more information on the “Knowledge for Growth” conference please visit: www.knowledgeforgrowth.be/en
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ion used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
